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ABSTRACT  
 
Objectives: Human Immunodeficiency Virus (HIV) infection can induce neurocognitive 
complications classified as HIV-associated neurocognitive disorder (HAND). The most 
severe form of HAND is HIV-associated dementia (HAD). It is very likely that HAD is a 
secondary response to innate immunity activation induced by HIV infection. The chitinase 
family is associated with innate immunity cells; the expression of chitinase family members 
is greatly amplified during many infections, highlighting their potential biological roles in 
inflammatory diseases and in innate immunoactivation. In this study, we have investigated 
the relationship between chitinases and macrophage/microglial activation in the brain of 
HAD.  
Methods: We analyzed microarray datasets obtained from NCBI 
(http://www.ncbi.nlm.nih.gov/) under accession number GDS4214 to examine the expression 
of chitinase family genes in hippocampal specimens of uninfected rhesus macaques (animal 
control) versus those with histopathologic evidence of Simian Immunodeficiency Virus 
Encephalitis (SIVE). All SIV-infected monkeys had neuropathological evidence of SIVE on 
post-mortem histopathological examination. A portion of hippocampus was preserved frozen 
at necropsy for later RNA extraction. The brain viral load (BVL) was determined on a sample 
of frontal lobe, containing both grey and white matter, and is given in log (10) viral genome 
equivalents per microgram RNA. For these studies, we also used the open source tools 
Genome-scale Integrated Analysis of gene Networks in Tissues (GIANT) to identify the 
chitinase genes network.  
Results: CHIT1, CHI3L1 and CHI3L2 mRNA levels were significantly increased in SIVE 
hippocampus as compared to non-infected control specimens (p=0.0009, p=2.66E-13 and 
p=2.53E-12, respectively). Furthermore, we found a negative correlation between CHIA vs  
BVL (r= -0.829 and p=0.006) and positive correlation between C1s and CHIA (r=0.837 and 
p=0.0050), CHIT1 vs  CHI3L2 and SLC11A1 (r=0.901, p=0.001; r=0.798, p=0.01 
respectively), CHI3L2 vs  CHID1 (r=0.782, p=0.013) and CHID1 vs  SLC11A1 (r=0.880, 
p=0.002).  
Conclusions: These results suggest that chitinase gene expression is altered in SIVE and call 
for more studies examining whether this is a protective immunological reaction or a 
destructive tissue response to SIV infection.  
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INTRODUCTION 
Human Immunodeficiency Virus (HIV) infection can induce neurocognitive complications 
classified as HIV-associated neurocognitive disorder (HAND) [1]. According to standardized 
measures of cognitive dysfunction, it is possible to define three stages of HAND: 
asymptomatic neurocognitive impairment (ANI), mild neurocognitive disorder (MND) and 
HIV-associated dementia (HAD) [2]. The most severe form of HAND is HAD [3]. This 
condition, characterized by cognitive dysfunction, motor disorders and deficits in learning 
and memory, occurs in less than 5% of people who have access to antiretroviral therapy [4]. 
Highly active antiretroviral therapy (HAART), a major advance in the treatment of HIV 
infection, has improved the survival of HIV patients [5]. As HIV patients now live longer, the 
prevalence of HAND has increased [6]. HAD correlates better with activation of brain 
mononuclear phagocytes (macrophages and microglia) than with quantitative measures of 
brain infection [7]. It is very likely that HAD is a secondary response to innate immunity 
activation induced by HIV infection [7,8]. In fact, HIV-1 can infect macrophages and 
microglia directly via gp120 binding, which in turn may induce the release of pro-
inflammatory factors and proteins that can be recognized as markers of microglial activation. 
Macrophages/microglial express CCR5 and CXCR4 [9] that are chemokine receptors on their 
surface in addition to CD4 [10] and viral gp120 binds via these receptors. The neurons and 
astrocytes have been reported to also possess CXCR4 and CCR5 receptors on their surface 
[11]. During the HIV-1 infection the macrophage/microglial enhances their production of 
lysosomal vesicles and here the virus is assembled and acquires antigens characteristic of this 
compartment [12].  
 
The chitinase family is an ancient gene family, which has evolved to hydrolyze chitin and its 
derivative [13,14]. The chitinase family includes proteins both with and without 
glycohydrolase enzymatic activity against chitin, which are expressed in cells of the innate 
immune system. Chitotriosidase (CHIT1) and acidic mammalian chitinase (CHIA or 
AMCAse) are the only two true chitinases possessing chitinolytic activities [8]. The other 
members, chitinase-like-lectins (Chi-lectins) or chitinase-like proteins (C/CLPs), including 
chitinase 3-like-1 (CHI3L1, also called YKL40 or HC-gp39), chitinase 3-like-2 (CHI3L2, 
CHIL2, YKL-39), chitinase domain containing 1 (CHID1), are structurally homologous to 
CHIT1 and CHIA but lack the essential catalytic residues with the preservation of the 
substrate-binding cleft of the chitinases [15].  
Chitinase expression is greatly amplified during many infections, highlighting their potential 
biological roles in inflammatory diseases and in innate immunoactivation [16,17]. CHIT1 and 
CHI3L1 have been reported to be upregulated in a variety of neurological degenerative 
disorders [18-20]. In cerebrospinal fluid (CSF) from AD patients, CHIT1 and CHI3L1 levels 
were higher compared to those found in neurologically normal control individuals [21-23]. 
Furthermore, high CHIT1 levels in CSF from ALS patients suggested a possible role in 
disease progression [18,24]. Most of these studies suggest that increase CSF chitinase activity 
reflects microglial activation as a response to or contributing factor in neurodegeneration. 
Recently, CHI3L1 was associated to the dendritic cell activation and differentiation [17].  
High CSF CHI3L1 levels were recently described in macaques and humans with lentiviral 
encephalitis [25]. In addition, it has been shown that CHI3L1 expression may be induced in 
astrocytes in traumatic brain injury [26].  
CHI3L2, another chitinase family member, has been reported to be overexpressed in AD 
brains [27]. Recently, increased CSF levels of CHI3L2 were measured in multiple sclerosis 
[28]. It is also one of the most expressed genes in glioblastomas but its function remains still 
obscure [29,30].  
CHIA is one of the enzymes with true chitinase activity [31]. The relatively abundant 
expression of CHIA in the gastrointestinal tract and lung supports a possible role in the 
mucosal immune system and potentially also as a digestive enzyme [32]. The precise role of 
CHIA in immune-mediated diseases is not clear but many reports suggesting that chitinase 
activity exerts a beneficial effect by negatively regulating chitin-induced tissue infiltration of 
innate immune cells associated with allergy [33]. Some studies suggest that CHIA activity 
may be needed in the brain to protect from protozoan infections [34].  
 
Very scarce information is available on CHID1. It can be used as a marker of alternative 
macrophage activation [35] and is expressed in some brain tumours [36]. Furthermore, 
CHID1 is expressed by specialized tissue macrophages (placenta, skin, gut and pancreas) and 
in cardiac and skeletal muscle by sinusoidal endothelial cells in liver, spleen, bone marrow 
and lymph nodes [37].  
In this study, we test the hypothesis that chitinase expression may be regulated during 
macrophage and microglial activation in a macaque model of HAD. 
 
METHODS 
Selection of a microarray expression dataset and bioinformatics analysis 
For this study, we analyzed microarray datasets obtained from NCBI 
(http://www.ncbi.nlm.nih.gov/) under accession number GDS4214 in order to examine 
mRNA levels of chitinase family genes in hippocampus specimens of uninfected rhesus 
macaques (animal control) versus those with histopathologic evidence of Simian 
Immunodeficiency Virus Encephalitis (SIVE). The MultiExperiment Viewer (MeV) software 
was used to identify different expression of chitinase genes and to generate expression 
heatmaps. In cases where multiple probes insisted on the same NCBI GeneID, we used those 
with the highest variance. Groups studied was constituted by 18 male rhesus macaques free 
of SIV, type D simian retrovirus and Herpes B virus. Nine monkeys were intravenously 
inoculated with a cell-free stock of a derivative of SIVmac251 that had been subjected to in 
vivo passage [38] [39]. The SIV-infected monkeys were sacrificed after development of 
neurological signs of simian AIDS, after a range of 56–132 (mean, 92; median, 93) days post-
inoculation. All SIV-infected monkeys had neuropathological evidence of SIVE on post-
mortem histopathological examination. A portion of hippocampus was preserved frozen at 
necropsy for later RNA extraction. The brain viral load (BVL) was determined on a sample 
of frontal lobe, containing both grey and white matter, and is given in log (10) viral genome 
equivalents per microgram RNA.  
Complete experimental details can be retrieved in the publication by Gersten M et al [40].  
For the chitinase gene pathway we used GIANT database (http://giant.princeton.edu/) setting 
the tissue menu in Hippocampus, the Network filter with Minimum relationship confidence 
0.13 (mininum 0; maximum 1) and Maximum number of genes in 5 (minimum 1; maximum 
50) to reduce the genes number to only with high average edge score (ES). No enriched 
biological processes were found. The relationship confidence score (Edge score) indicate how 
two genes are co-expressed in the same tissue.  
GIANT leverages a tissue-specific gold standard to automatically up-weight datasets relevant 
to a tissue from a large data compendium of diverse tissues and cell-types. GIANT was 
created by the Laboratory for Bioinformatics and Functional Genomics in the Lewis-Sigler 
Institute for Integrative Genomics at Princeton University. GIANT tissue networks integrate 
987 genome-scale datasets, encompassing ~38,000 conditions from ~14,000 publications and 
include both expression and interaction measurements. The resulting functional networks 
accurately capture tissue-specific functional interactions. These maps can answer biological 
questions that are specific to a single gene in a single tissue. This software can effectively 
reprioritize functional associations from a genome-wide association study (GWAS) and 
potentially identify additional disease-associated genes. The approach, named NetWAS, can 
be applied to any GWAS study, and does not require that the phenotype or disease have any 
known associated genes [41].  
Statistical analysis 
Data are expressed as intensity expression levels and presented as box and whiskers. For 
statistical analysis, Prism 7 software (GraphPad Software, La Jolla, CA, USA) and SPSS 20.0 
for IBM was used. Parametric tests were used. One-way ANOVA and t-tests with Bonferroni 
correction were used to analyze the data and significance was determined at *p<0.05; 
**p<0.005;***p<0.0005. Correlations were determined using Pearson’s correlation. 
 
RESULTS 
SIVE Hippocampus expresses significant high levels of Chitinases mRNA  
The GDS4214 microarray analysis showed a significant regulation of three chitinases out of 
five in rhesus macaques hippocampus with histopathologic evidence of SIVE compared to 
the animal control. The only chitinase with chitinolytic activity, CHIT1, was expressed at 
significantly higher mRNA levels in SIVE hippocampus compared to control hippocampus 
(p=0.0009, Figure 1A). No significant regulation was observed for CHIA (p=0.28) (Figure 
1B). CHI3L1 and CHI3L2 mRNA levels were significant upregulated in SIVE hippocampus 
(p=2.66E-13 and p=2.53E-12, respectively) compared with control (Figure 2A and B). No 
significant regulation was observed for CHID1 mRNA (p=0.27) when comparing the two 
groups (Figure 2C). These data confirm innate immunity activation in the hippocampus in 
SIVE.  
 
Hippocampus chitinase network analysis reveals significant regulation in SIVE  
To verify the chitinase activation in SIVE hippocampus, we performed a GIANT analysis 
(http://giant.princeton.edu/). The software identified the hippocampus network genes related 
to the chitinases. The analysis showed that CHIT1 was co-expressed in hippocampus with 
SLC11A1 (ES=0.332), TRIM10 (ES=0.269), P2RX6 (ES=0.267), APOC4 (ES=0.267) and 
ARHGEF15 (ES=0.264) (Figure 3A).  We decided to perform an expression analysis of 
SLC11A1 mRNA in SIVE hippocampus and found a significant upregulation (p=0.00059) 
compared with control hippocampus (Figure 3A). The other gene network analysis showed 
that TRIM10, P2RX6, APOC4 mRNA were significantly regulated in SIVE hippocampus 
(Figure 4A) compared with control hippocampus. No significant regulation was observed in 
ARHGEF15 mRNA when comparing the two groups.  
We identified the following genes to be co-regulated in hippocampus with CHI3L1: C1S 
(ES=0.230), PMP22 (ES=0.224), MT1B (ES=0.206), HOMER3 (ES=0.199) and PTK2 
(ES=0.194). Only C1S, PMP22 and HOMER3 mRNAs were significantly regulated in SIVE 
hippocampus compared control hippocampus (Figure 4B). The expression of the highly co-
expressed CS1mRNA showed a significant regulation in hippocampus of SIVE compared to 
control hippocampus (Figure 3B). The CHI3L2 network analysis showed the following genes 
to be co-regulated with CHI3L2: SMOX (ES=0.315), DCBLD2 (ES=0.312), LDLRAD4 
(ES=0.247), ADAMTS2 (ES=0.239) and RRAD (ES=0.235). The gene with the highest 
score, SMOX, was significantly regulated in SIVE hippocampus (p= 1.17E-05) compared 
with control hippocampus (Figure 3C). Among the other genes belonging to the network, 
SMOX, DCBLD2, LDLRAD4 and ADAMTS2 mRNAs were significantly regulated in SIVE 
hippocampus (Figure 4C). No significant regulation was observed for RRAD mRNA 
(p=0.78).  
 
Chitinases family correlation with brain viral load 
To examine if the chitinases were correlated with the BVL, we performed a Pearson’s 
correlation of chitinases expression in SIV-infected monkeys who presented 
neuropathological evidence of SIVE. The BVL is expressed in log(10) viral genome 
equivalents per microgram RNA [40] (Figure 5A). The analysis showed a strong positive 
correlation between the BVL and C1s (r=0.955, p=0.0007) (Figure 5B; Figure 6 and Table 1). 
Among the chitinases, only CHIA showed a negative correlation with BVL (r= -0.829 and 
p=0.006) (Figure 5C) (Figure 6) (Table 1). Positive correlation between C1s and CHIA 
(r=0.837 and p=0.0050) was observed too (Figure 5D) (Figure 6 and Table 1). Positive 
correlations between chitinases and their gene network were found for CHIT1 vs. CHI3L2 
and SLC11A1 (r=0.901, p=0.001; r=0.798, p=0.01 respectively); CHI3L2 vs. CHID1 
(r=0.782, p=0.013); CHID1 vs. SLC11A1 (r=0.880, p=0.002) (Figure 6 and Table 1).  
DISCUSSION 
In the present study, we have analyzed the transcriptomic profiles of chitinase gene family 
members in hippocampus specimens of macaques with SIVE. We showed that three 
chitinases (CHIT1, CHI3L1 and CHI3L2) among five were regulated during the virus 
encephalitis. Beside this, the most important chitinases related to the gene network in the 
hippocampus weere significantly regulated in SIVE. Additionally, we found that CHIA was 
negatively correlated with C1s mRNA levels and BVL.   
 
To our knowledge, there is no information concerning the association between CHIT1 
expression and SIVE. Our study is the first that assesses this relationship. The CHIT1 
expression is linked to macrophages activation and with several lysosomal disorders, 
especially in Gaucher’s disease [16,42].  Yasemin Gulcan et al. associated the serum CHIT1 
enzyme activity with mortality from Crimean-Congo hemorrhagic fever virus [43] and this is 
to our knowledge the only known link between CHIT1 and virus infection so far. The CHIT1 
mRNA transcription in hippocampus infected by HIV-1 virus could be attributed to 
microglia/macrophage activation in the CNS. Macrophages or microglia infected by HIV 
release viral proteins, pro-inflammatory cytokines and chemokines, which in turn activate 
uninfected macrophages and microglia [44]. These activated cells may release brain 
neurotoxic substances over prolonged time periods inducing neuronal injury, synapse 
damage, and cell death [44]. There are at least three forms of microglial activation during 
HIV infection: M1 (during the early infection); M2a and M2c (during the intermediate and 
late infection) [45]. The M1 activation  pattern inhibits viral entry, assembly, and budding but 
it is also known that pro-inflammatory signals (TNF, IL1 and IL6) may promote the 
formation of viral reservoirs with increased transcription of  HIV-1 LTR (long terminal 
repeat) [46,47]. A transition from M1 to M2 status is associated with neuroprotection in the 
case of HIV-associated neurocognitive disorders, suggesting M2 may curtail the M1-HIV 
polarized activity resulting in tissue damage [48]. In concordance with these data, it has been 
seen that CHIT1 expression is upregulated in M2 macrophages [48]. HIV-1 infection 
increases expression and secretion of beta-amyloid (Aβ) and Aβ peptides [49]. Moreover, it 
has been hypothesized that chitin-like polysaccharides provide a scaffolding for amyloid-beta 
deposition [50]. In this context, the CHIT1 could interact with amyloid-beta via chitin-like 
polysaccharides. All these activation patterns and correlations provide indirect support for an 
association between HIV/SIV-induced microglial activation and neurodegenerative 
processes, which is reflected by altered transcriptional regulation of multiple players in 
chitinase-related gene networks.  
Beside this, in our analysis we found that SLC11A1 mRNA was significantly upregulated in 
SIVE and there is a positive correlation with CHIT1 expression. These results are in 
accordance with the role played in Central Nervous System (CNS) by SLC11A1 [51]. The 
proton-divalent cation transporters encoded by SLC11A1 is expressed in the brain and 
regulate ion homeostasis from endosomal compartments. SLC11A1 also has pleiotropic 
effects on pro-inflammatory responses that may be important in AD [51]. Furthermore, 
higher concentrations of IL-33, an inflammatory cytokine expressed in the CNS and in 
activated microglia cells, in HIV clade B infection was showed to be   associated with an 
increased levels of SLC11A1 [52]. All these data corroborate our findings and the possible 
role played by the CHIT1 network in the SIVE. 
Regarding chitinases with true enzymatic activity, we found that CHIA mRNA is negatively 
correlated to BVL. This result could be explanation in the polarization of the macrophages.  
CHIA expression is linked to the M2 macrophages, occurring during the IL13 pathways 
activation [53]. The BVL increase indicates an active state of hippocampus infection, which 
should correlate with a M1 microglial activation pattern [54].  This data was confirmed by the 
positive correlation found between C1s (a complement molecule secreted by microglia under 
stimulation of pro-inflammatory cytokine) and BVL [55].  Therefore, it seems very likely that 
the M1 to M2 macrophage polarization determines the reduced expression of CHIA mRNA.  
In 2008 Bonneh-Barkay and colleagues [25] found that the CHI3L1 expression was elevated 
fivefold in CSF of SIVE cases versus non-encephalitis cases but the origin and functions in 
the CNS are still unknown. Furthermore, they showed a positive correlation between CHI3L1 
and CSF viral load. Our result partially confirmed this finding. We found a significant mRNA 
upregulation of CHI3L1 in SIVE hippocampus but no significant correlation was found 
toward BVL. This discrepancy it could be explained through the possible role played by 
CHI3L1 during the infection. The CHI3L1 upregulation is connected to the immuno-
activation and chemotaxies [56]. Neurodegeneration is associated with increased microglial 
activation and the recruitment of innate immunity system [57]. In this process the CHI3L1 
could play an important role during the SIVE neuronal damage. In vitro experiments showed 
that CHI3L1 produces extracellular matrix (ECM) damage through macrophages activation 
[58]. The association between CHI3L1, inflammation, and macrophages might have 
particular relevance for neuroinflammation associated with dementia. The virus infection 
could induce CHI3L1 expression and the resulting effects in the CNS as well as innate 
immunity activation occur, possibly qualifying CHI3L1 as a biomarker for SIVE. 
CHI3L2 is strongly expressed in the brains of MS patients, especially in astrocytes and 
microglial cells in the white matter plaques [28]. This data could better support our results 
justifying the high CHI3L2 mRNA levels detected in SIVE hippocampus. These results could 
be correlated to the role played by this molecule in the brain tissue. Furthermore, it has been 
shown that CHI3L2 could regulate the angiogenesis in the brain tumours [29] [59]. The 
angiogenesis dysregulation represents a new pathogenic mechanism involved in the 
progression of Alzheimer's and neurodegenerative diseases [60]. Moreover, it has been 
shown that HIV-1 Tat increases the levels of molecules involved in cell migration, 
angiogenesis, neurogenesis and synaptic plasticity. The CHI3L2 upregulation in SIVE could 
be correlated to the lysosomal immuno-activation of microglia/macrophages induced by 
HIV1 virus. Furthermore, our analysis showed that CHI3L2 is also positively correlated to 
SCL11A1, CHID1 and CHIT1 in SIVE hippocampus. These data confirm even more the 
chitinases family network implication in the brain degenerative process.  
In conclusion, these findings support a role of chitinase family network in SIVE. The data 
may be extended to both neurodegenerative and neuroinflammatory diseases. The strong 
transcriptional changes detected in our analyses suggest that the protein products of these 
genes should be examined further as potential biomarkers for microglial activation in several 
neurological diseases.  
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FIGURE LEGENDS 
Figure 1: Chitinase expression levels in SIVE hippocampus section.  
A) Expression levels of true chitinases reveal upregulation of CHIT1 (p=0.0009) in SIVE 
hippocampus compared to control hippocampus. B) No significant regulation was observed 
in the CHIA expression levels (p=0.28). Dataset accession number GDS4214. Data are 
expressed as intensity expression levels and presented as box and whiskers. P values <0.05 
were considered to be statistically significant (*p<0.05; **p<0.005;***p<0.0005).   
Figure 2: Chitinases like protein expression levels in SIVE hippocampus section. 
A) and B) The chitinase-like lectins, CHI3L1 and CHI3L2, were high significant upregulated 
in SIVE hippocampus (p=2.66E-13 and p=2.53E-12, respectively). C) CHID1 mRNA levels 
are unaltered in SIVE hippocampus (p=0.27).  Dataset accession number GDS4214. Data are 
expressed as intensity expression levels and presented as box and whiskers. P values <0.005 
were considered to be statistically significant (*p<0.05; **p<0.005;***p<0.0005).   
Figure 3: Hippocampal network analysis of chitinase-related genes 
Hippocampal chitinase gene network analysis was performed using the GIANT software 
(http://giant.princeton.edu/). The figure shows the network hippocampus analysis for each 
chitinases; the relationship confidence score for the genes network referred to the chitinase; 
the most chitinase-related genes in SIVE hippocampus section compared to the control group. 
Edge thickness and colour correspond to edge strength. Dataset accession number GDS4214. 
Data are expressed as intensity expression levels and presented as box and whiskers. P values 
<0.005 were considered to be statistically significant (*p<0.05; **p<0.005;***p<0.0005). 
Figure 4: Chitinase genes network statistical significance in SIVE hippocampus section 
The figure shows the Radar chart of chitinases significant genes network and heatmap of 
medium expression levels in SIVE hippocampus section. Gene expression values are color 
coded from bright red (most upregulated) to dark blue (most downregulated). No significant 
genes are marked in red.  
Figure 5: Chitinase correlation with brain viral load  
A) SIV-infected monkeys BVL was determined on a sample of frontal lobe, containing both 
grey and white matter, and is given in log (10) viral genome equivalents per microgram RNA. 
C1s expression levels show a strong positive correlation with BVL (B) and negative with 
CHIA (D). As regard the expression levels of CHIA, these were correlated negatively with 
BVL (C).  
Figure 6: Chitinases genes network correlation 
Positive correlation was found between BVL and C1s (r=0.955 and p=0.0007); CHIT1 vs  
CHI3L2 and SLC11A1 (r=0.901 and p=0.001; r=0.798 and p=0.01 respectively); CHI3L2 vs  
CHID1 (r=0.782 and p=0.013); CHID1 vs  SLC11A1 (r=0.880 and p=0.002). Negatively 
correlation was found between CHIA and BVL (r=-0.829 and p=0.0060) and a positive one 
between C1s and CHIA (r=0.837 and p=0.0050). The genes correlated are showed in red box 
square box.  
Graphical abstract: Chitinases expression in macrophages/microglia SIVE 
hippocampus.  
HIV-1 shows a tropism for brain cells. The microglia cells express surface markers like 
CXCR4, CXCR5 and CD4. These markers are used by the HIV-1 virus to infect the 
microglia. Activated microglia increase the production of lysosomal vesicles as well as 
chitinases. CHI3L1 and CHI3L2 increase cell migration and chemotaxis. Macrophages 
recruited by the chitinases infiltrate the brain and here become polarized (M1/M2). The brain 
infiltrating macrophages now became target of HIV-1 virus. Secreted CHIT1 can interact 
with beta-amyloid plaque via Chitin-like polysaccharides. All this may contribute to neuronal 
injury and death induced by HIV-1 infection.  
Table 1: Correlation analysis between chitinase hippocampal gene networks vs. BVL  
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